Citadel Advisors
ELDN icon

Citadel Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Citadel Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,300
Closed -$45.8K – 13265
2025
Q4 		$45.8K Sell
30,300
-3,100
-9% -$7.37K ﹤0.01% 12070
2025
Q3 		$86.5K Buy
33,400
+3,100
+10% +$9.06K ﹤0.01% 11931
2025
Q2 		$82.1K Sell
30,300
-15,500
-34% -$46.5K ﹤0.01% 11479
2025
Q1 		$155K Buy
45,800
+43,100
+1,596% +$177K ﹤0.01% 10825
2024
Q4 		$11.1K Buy
+2,700
New +$10.6K ﹤0.01% 13567
2024
Q2 		– Sell
-1,400
Closed -$2.88K – 14514
2024
Q1 		$2.88K Buy
+1,400
New +$2.5K ﹤0.01% 13964
2023
Q3 		– Sell
-4,600
Closed -$6.3K – 14491
2023
Q2 		$6.3K Buy
4,600
+3,200
+229% +$6.67K ﹤0.01% 13434
2023
Q1 		$3.3K Buy
+1,400
New +$3.75K ﹤0.01% 14051
2022
Q2 		– Sell
-17,500
Closed -$69K – 13140
2022
Q1 		$69K Buy
+17,500
New +$67.8K ﹤0.01% 12586

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citadel Advisors's ELDN Position: Q3 2025 in Review

Citadel Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 152,460 shares — an estimated $446K sold.

Citadel Advisors first reported a position in ELDN in Q2 2019 and held it in 12 quarters. The position peaked at $782K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Citadel Advisors reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 152,460 Eledon Pharmaceuticals shares in Q3 2025, an estimated $446K.
  • Citadel Advisors first reported a position in Eledon Pharmaceuticals in Q2 2019 and held it in 12 quarters.
  • Citadel Advisors's Eledon Pharmaceuticals position peaked at $782K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.